Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Coprescription of Triptans and SSRI-type Medications and the Serotonin Syndrome
    ABSTRACT & COMMENTARY

    Coprescription of Triptans and SSRI-type Medications and the Serotonin Syndrome

    April 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Triptans and Serotonergic Medications in Migraine Patients: Should We Worry?

    Psychiatric Drug Combinations and the Serotonin Syndrome

    How Safe Are New Medications for Type 2 Diabetes?

    Related Products

    The Role of Ginger in Type 2 Diabetes Mellitus

    Serotonin Transporter Increases in Premotor Parkinson’s Disease

    Keywords

    Antidepressants

    syndrome

    triptan

    serotonin

    By Louise M. Klebanoff, MD

    Assistant Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Klebanoff reports no financial relationships relevant to this field of study.

    SYNOPSIS: A recent study provided reassurance that the use of triptan antimigraine medications with selective serotonin reuptake inhibitor and selective norepinephrine reuptake inhibitor antidepressants is safe.

    SOURCE: Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018 Feb. 26. doi:10.1001/jamaneurol.2017.S144. [Epub ahead of print].

    Depression and migraine are highly prevalent, chronic disorders that occur together more often than would be expected by chance. Selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) commonly are used to treat depression. Triptan antimigraine drugs commonly are prescribed to treat migraines. Evidence has suggested that between 20-25% of triptan users also are prescribed SSRI or SNRI antidepressants. There have been several case reports of serotonin syndrome in patients coprescribed these medications.

    Serotonin syndrome is thought to result from elevated serotonin levels. Patients present with variable symptoms, including tachycardia, unstable blood pressure, hyperthermia, nausea, vomiting, and diarrhea. Although the severity is variable, the condition can be fatal. In 2006, the FDA issued an advisory about the risk of serotonin syndrome associated with concomitant use of triptan antimigraine medications with SSRIs and SNRIs. Following the FDA advisory, pharmacy systems and other decision support systems started issuing safety alerts when coprescription occurs. These alerts can disrupt clinical care. Neurologists treating migraine infrequently have seen serotonin syndrome in clinical practice. A position paper by the American Headache Society questioned the validity of the FDA advisory.

    The authors conducted a study to identify patients who were coprescribed triptans and SSRIs/SNRIs to assess the risk of serotonin syndrome. They used the Partners Research Data Registry to identify patients who had been coprescribed triptans and SSRIs/SNRIs from Jan. 1, 2001, through Dec. 31, 2014. Investigators searched the records for serotonin syndrome and other extrapyramidal diseases and abnormal movement disorders, and then one investigator reviewed the results to assess if the patients met diagnostic criteria (either Sternbach criteria or Hunter criteria) for serotonin syndrome. The overall incidence rate for serotonin syndrome was determined by dividing the number cases by the person-years at risk during the study period.

    The authors identified 47,968 patients who were prescribed triptans during the 14-year study period, with 19,017 patients also prescribed an SSRI or SNRI. Of these 19,017 patients, 229 (0.01%) had a diagnosis of extrapyramidal syndrome at some point in time, with serotonin syndrome clinically suspected in 17 patients. In only two cases, triptans were used in close temporal relation to the development of symptoms; in both cases, symptoms actually started prior to ingesting the triptan. Only seven cases occurred during a year in which coprescription of triptans and an SSRI or SNRI was documented in the medical record. In more than 30,000 patient-years of exposure, there were no life-threatening cases of serotonin syndrome and no cases in which triptan use was unequivocally implicated as a cause. The estimates suggest that the incidence of serotonin syndrome in patients coprescribed triptans and SSRIs or SNRIs ranged from zero to four cases per 10,000 person-years of exposure.

    COMMENTARY

    Serotonin syndrome is rare in patients who are coprescribed SSRI or SNRI antidepressants and triptan antimigraine medications. From a biological perspective, it is uncertain how triptans, which are serotonin agonists with high affinity for serotonin 1B and 1D receptors, could cause serotonin syndrome, which is thought to be mediated by serotonin 2A receptors. This study provides additional reassurance regarding the safe use of triptan antimigraine medications with SSRI and SNRI antidepressants.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 37, No. 8) - April 2018
    April 1, 2018

    Table Of Contents

    Autoimmune Encephalitis: Not Rare and Increasing

    Coprescription of Triptans and SSRI-type Medications and the Serotonin Syndrome

    Postpartum Headache May Be a Symptom of a Serious Problem

    Lessons Learned From a Failed Anti-amyloid Trial for Alzheimer’s Disease

    Parsonage-Turner Syndrome: Where’s the Lesion?

    A Possible New Treatment for HTLV-1-associated Myelopathy

    Begin Test

    Buy this Issue/Course

    Pharmacology Watch

    Clinical Briefs in Primary Care

    Feedback? Please take our annual survey

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing